EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，本公司董事會包括(i)執行董事姚雪先生、沈洪敏女士、郭家平先生及劉紅嬋女士；及(ii)獨立非執行董事疏義傑先 生、黃素珍女士及謝東先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 武漢大眾口腔醫療股份有限公司 | | 股份代號 | 02651 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月31日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年 ...

Financial Performance - Revenue decreased by 8.7% from RMB 407.1 million for the year ended December 31, 2024, to RMB 371.6 million for the year ended December 31, 2025[4] - Net profit decreased by 19.0% from RMB 62.5 million for the year ended December 31, 2024, to RMB 50.6 million for the year ended December 31, 2025[4] - Adjusted net profit (non-IFRS measure) decreased by 11.1% from RMB 68.3 million for the year ended December 31, 2024, to RMB 60.7 million for the year ended December 31, 2025[4] - Total revenue for 2025 was RMB 371,571 thousand, a decrease of 8.7% from RMB 407,083 thousand in 2024[11] - Revenue from orthodontic services in 2025 was RMB 70,643 thousand, down 4.0% from RMB 74,115 thousand in 2024[11] - Revenue from dental implant services decreased by 14.9% to RMB 98,400 thousand in 2025 from RMB 115,647 thousand in 2024[11] - Comprehensive dental treatment services revenue fell to RMB 202,528 thousand, a decline of 6.8% from RMB 217,321 thousand in 2024[11] - Pre-tax profit for 2025 was RMB 28,175 thousand, down 32.8% from RMB 41,916 thousand in 2024[21] - Gross profit decreased by 8.0% from RMB 152.3 million to RMB 140.1 million, while gross margin increased from 37.4% to 37.7% due to effective cost control[48] - Net profit decreased by 19.0% from RMB 62.5 million to RMB 50.6 million, with net profit margin declining from 15.4% to 13.6%[53] Operational Highlights - The number of patient visits reached 729,404, with 159,535 new patient visits during the year ended December 31, 2025[4] - The company opened 8 new dental clinics and 2 dental offices during the year ended December 31, 2025[4] - The company operates a growing dental service network under the unified brand "Aishang Dazhong Dental" in Hubei and Hunan provinces[24] - The company opened 8 new dental clinics and 2 dental offices in 2025, bringing the total to 92 dental medical institutions, including 4 hospitals, 80 clinics, and 8 offices[25] - As of December 31, 2025, 54.8% of dentists held intermediate or higher professional titles, ensuring high-quality medical services[34] - The company has a total of 1,015 employees, with 932 (92%) working in dental medical institutions[33] Financial Position - Total assets minus current liabilities increased from RMB 242.9 million in 2024 to RMB 424.0 million in 2025[6] - Cash and deposits increased significantly from RMB 95.0 million in 2024 to RMB 251.5 million in 2025[6] - Total liabilities decreased from RMB 218.98 million in 2024 to RMB 140.71 million in 2025[7] - Net assets increased from RMB 159.01 million in 2024 to RMB 374.27 million in 2025[7] - Trade receivables increased to RMB 7,415 thousand in 2025 from RMB 5,836 thousand in 2024[22] - Trade payables decreased to RMB 9,778 thousand in 2025 from RMB 14,678 thousand in 2024[23] - The current ratio improved to 3.4 times as of December 31, 2025, compared to 0.9 times as of December 31, 2024[58] - Cash and deposits increased from RMB 95.0 million as of December 31, 2024, to RMB 251.5 million as of December 31, 2025, primarily due to increased funds raised from the listing[58] Dividend and Shareholder Information - Proposed final dividend of RMB 0.668 per share (tax included) for the year ended December 31, 2025[4] - The company proposed a final dividend of RMB 0.668 per share, totaling RMB 32,985 thousand, pending shareholder approval[19] - The board proposed a final dividend of RMB 0.668 per share, totaling RMB 32,985,200, subject to shareholder approval at the 2025 annual general meeting[71] - The proposed final dividend is expected to be distributed no later than June 30, 2026, contingent upon shareholder approval[71] - The 2025 annual general meeting is scheduled for May 29, 2026, with relevant documents to be sent to shareholders[75] - Share transfer registration will be suspended from May 26 to May 29, 2026, to determine the list of shareholders eligible to attend and vote at the annual general meeting[76] - A similar suspension of share transfer registration will occur from June 4 to June 5, 2026, to determine shareholders eligible for the proposed final dividend[77] - The annual report for the year ending December 31, 2025, will be sent to shareholders and published on the company's and the stock exchange's websites[78] Strategic Outlook - The company aims to enhance operational efficiency and profitability in the central China market, focusing on fine-tuned operations and cost control[37] - The company plans to pursue high-quality expansion through strategic acquisitions and self-built facilities, emphasizing investment returns[38] - The Chinese dental medical service market is projected to reach RMB 200.4 billion by 2029, driven by increasing health management awareness and demographic changes[35] - The central China region is expected to see dental service demand continue to grow, outpacing the national average growth rate[36] - The company is committed to a market strategy that focuses on Wuhan, covering Hubei and radiating throughout central China[37] Cost Management and Efficiency - Administrative expenses decreased by 16.3% from RMB 34.9 million to RMB 29.2 million, primarily due to optimization of functional and personnel structure[51] - Sales and distribution expenses increased by 4.8% from RMB 40.5 million to RMB 42.4 million, mainly due to increased advertising and promotional expenses[50] - Cost management strategies resulted in a 5% reduction in operational expenses, improving overall profitability[84] Market Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 5 billion in Q3 2023[84] - User data showed a growth of 20% in active users, totaling 10 million by the end of the quarter[84] - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting RMB 5.5 billion[84] - New product launches contributed to a 25% increase in sales, with three new products introduced in the last quarter[84] - Market expansion efforts have led to a 30% increase in market share in Southeast Asia[84] - The company completed a strategic acquisition of a competitor for RMB 1 billion, expected to enhance its product offerings[84] - The company plans to enter the European market by Q2 2024, targeting a revenue contribution of RMB 500 million[84] - Customer satisfaction ratings improved by 15%, reflecting the success of recent service enhancements[84]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 武漢大眾口腔醫療股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，本公司將於2026年3月31日（星期二）舉行董事會會議，藉以（其中包括）考慮 及批准本公司及其附屬公司截至2025年12月31日止年度的全年業績及其發佈，並 考慮建議派發末期股息（如有）。 承董事會命 武漢大眾口腔醫療股份有限公司 董事長兼執行董事 姚雪先生 Wuhan Dazhong Dental Medical Co., Ltd. 中國湖北省武漢市 2026年3月19日 武漢大眾口腔醫療股份有限公司 於本公告日期，本公司董事會包括(i)執行董事姚雪先生、沈洪敏女士、郭家平先 生及劉紅嬋女士；及(ii)獨立非執行董事疏義傑先生、黃素珍女士及謝東先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2651） 董事會召開日期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 | RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 | RMB | | 17,026,140 | | 2. 股份分類 | 普通股 ...

Group 1 - The stock price of Dazhong Oral (02651.HK) reached a historical low of 9.500 HKD on February 5, and closed at 9.60 HKD on February 13, marking a daily increase of 5.61% [1] - On February 13, the trading volume was 6,000 shares, with a transaction amount of 54,863 HKD, indicating significant price volatility with an amplitude of 7.26% [1] Group 2 - The rebound in stock price on February 13 lacks a clear direct driving event according to public information [2] - Analysts suggest that Dazhong Oral has demonstrated profit resilience during the industry adjustment period, with a projected net profit of 28.6 million HKD for the first half of 2025 and a high net profit margin compared to peers [2] - The company has maintained a stable dividend policy, distributing over 125 million HKD in dividends over the past three years, which may have positively influenced market sentiment [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 | RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 | RMB | | 17,026,140 | | 2. 股份分類 | 普通股 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | | 1 RMB | | 17,026,140 | | 2. 股份分類 | 普通 ...

Summary of Key Points Core Viewpoint - As of November 21, 14 stocks reached their 52-week highs, with Hengfa Optical (01134), Chaowei Holdings (08059), and Cassava Resources (00841) leading the gains at 42.11%, 30.56%, and 22.49% respectively [1]. 52-Week Highs - Hengfa Optical (01134) closed at 0.375, with a peak price of 0.540, marking a 42.11% increase [1]. - Chaowei Holdings (08059) closed at 0.030, reaching a high of 0.047, reflecting a 30.56% rise [1]. - Cassava Resources (00841) closed at 0.200, with a maximum price of 0.207, indicating a 22.49% increase [1]. - Other notable stocks include Sibor Systems (08319) at 15.04%, MOS HOUSE (01653) at 11.46%, and Tianjin Jianfa (02515) at 5.19% [1]. 52-Week Lows - China Pengfei Group (03348) reached a low of 1.100, down 20.09% from its peak [1]. - China Information Technology (08178) closed at 0.285, reflecting a 19.35% decrease [1]. - XL Ernan Strategy - U (09799) saw a decline of 14.27% [1]. - Other significant declines include Hesai - W (02525) at -10.54% and MBC Bitcoin - U (03425) at -9.09% [1]. Additional Notable Stocks - Stocks like MBC Bitcoin (03430) and Tongyuan Kang Pharmaceutical - B (02410) also experienced declines of 6.64% and 6.62% respectively [2]. - The overall trend indicates a mix of significant gains in certain stocks while others are facing substantial losses, reflecting a volatile market environment [1][2].

致：香港交易及結算所有限公司 公司名稱: 武漢大眾口腔醫療股份有限公司 呈交日期: 2025年11月6日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02651 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 17,026,140 | RMB | | 1 RMB | | 17,026,140 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...